Johnson & Johnson (JNJ) and Merck (MRK) are cutting jobs in China as they face growing competition from domestic rivals resulting from Beijing’s campaign to drive down medical costs, Bloomberg’s Amber Tong reports. The cuts at J&J have mainly impacted a division that sells products used in surgery, while Merck has scaled back its diabetes unit, according to the report.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Protagonist and JNJ say icotrokinra study for PsO meets endpoint
- Johnson & Johnson announces results from ICONIC-LEADa Phase 3 study
- Eli Lilly sues to change hospital drug discount payments, WSJ reports
- Eli Lilly and Co (NYSE:LLY) Sues Federal Health Agency over Hospital Drug Discounts
- Wolfe starts J&J at Outperform, sees growth drivers as ‘best-in-class’